Cargando…

Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma

Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer development. The mitochondrial genomic aberrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raghav, Lovely, Chang, Ya-Hsuan, Hsu, Yi-Chiung, Li, Yu-Cheng, Chen, Chih-Yi, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Chuang, Cheng-Yen, Lee, Mei-Hsuan, Wang, Chih-Liang, Chen, Huei-Wen, Yu, Sung-Liang, Su, Sheng-Fang, Yuan, Shin-Sheng, Chen, Jeremy J.W., Ho, Shinn-Ying, Li, Ker-Chau, Yang, Pan-Chyr, Chang, Gee-Chen, Chen, Hsuan-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140061/ https://www.ncbi.nlm.nih.gov/pubmed/32210009 http://dx.doi.org/10.3390/cancers12030755

Ejemplares similares

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
por: Chen, Hsuan-Yu, et al.
Publicado: (2016)

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity
por: Hsu, Yi-Chiung, et al.
Publicado: (2013)

ePIANNO: ePIgenomics ANNOtation tool
por: Liu, Chia-Hsin, et al.
Publicado: (2016)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Molecular gene signature and prognosis of non-small cell lung cancer
por: Huang, Poyin, et al.
Publicado: (2016)

Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2016)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

The regional differences in prevalence, medical expenditures and risk factors for injury in Taiwanese teenagers
por: Chen, Huei-Yang, et al.
Publicado: (2006)

Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
por: Chang, Ya-Hsuan, et al.
Publicado: (2015)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Lactobacillus paragasseri BBM171 Ameliorates Allergic Airway Inflammation Induced by Ovalbumin in Mice via Modulating the Th1/Th2 Balance
por: Cheng, Shih-Hsuan, et al.
Publicado: (2022)

Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
por: Lai, Yi-Hua, et al.
Publicado: (2015)

SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma
por: Hsiao, Yi-Jing, et al.
Publicado: (2016)

Identification of Lactoferricin B Intracellular Targets Using an Escherichia coli Proteome Chip
por: Tu, Yu-Hsuan, et al.
Publicado: (2011)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

The Motor Protein KIF14 Inhibits Tumor Growth and Cancer Metastasis in Lung Adenocarcinoma
por: Hung, Pei-Fang, et al.
Publicado: (2013)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role
por: Hsiao, Yi-Jing, et al.
Publicado: (2020)

Bhlhe40 differentially regulates the function and number of peroxisomes and mitochondria in myogenic cells
por: Chang, Hsuan Chia, et al.
Publicado: (2018)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Risk of acute coronary syndrome after parathyroidectomy in patients with end‐stage renal disease: A population‐based cohort study in Taiwan
por: Ma, Tsung Liang, et al.
Publicado: (2018)

Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
por: Lin, Ching-Wen, et al.
Publicado: (2016)

Reconstruction of High-Grade Trochlea Dysplasia in a Young Female with Recurrent Patella Dislocation: A Case Report
por: Wu, Chih-Hsuan, et al.
Publicado: (2023)

The aqueous extract of Glycyrrhiza inflata can upregulate unfolded protein response-mediated chaperones to reduce tau misfolding in cell models of Alzheimer’s disease
por: Chang, Kuo-Hsuan, et al.
Publicado: (2016)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2022)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface
por: Chang, Yi-Wen, et al.
Publicado: (2023)

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2015)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Antireflection of optical anisotropic dielectric metasurfaces
por: Liao, Yu-Hsuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ekon667qbddn1hrvcush77m6rc